ESC Heart Failure 2016: Was gibt es Neues?

Ponikowski P et al (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 18(8):891–975 Papp Z et al (2012) Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol 159(2):82–87 Pollesello P et al (2016) Levosimendan meta-analyses: Is there a pattern in the effect on mortality? Int J Cardiol 209:77–83 Packer M et al (2013) Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail 1(2):103–111 Kirklin JK et al (2015) Seventh INTERMACS annual report: 15,000 patients and counting. J Heart Lung Transplant 34(12):1495–1504 McMurray JJ et al (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371(11):993–1004 Du XJ et al (2010) Cardiovascular effects of relaxin: from basic science to clinical therapy. Nat Rev Cardiol 7(1):48–58 Teerlink JR et al (2013) Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 381(9860):29–39 Anker SD et al (2009) Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361(25):2436–2448 Ponikowski P et al (2015) The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study. Eur J Heart Fail 17(3):329–339 Zinman B et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117–2128 Lam CS, Teng TH (2016) Minding the gap in heart failure: understanding the pulse pressure in reduced versus preserved ejection fraction. JACC Heart Fail 4(1):50–54